Behavioural Neurology / 2017 / Article / Tab 1

Research Article

Prevalence of Anxiety among Hungarian Subjects with Parkinson’s Disease

Table 1

Demographic and disease-specific data of the study population () participating in the validation phase.

Mean or countStandard deviation or percentage

Age (years)65.89.8
Sex
 Male11057.9%
 Female8042.1%
Education (years)12.53.2
Disease duration (years)7.26.4
Disease duration (years)7.26.4
Type of disease
 Tremor dominant6132.1%
 Akinetic rigid7941.6%
 Mixed5026.3%
Hoehn and Yahr Stage
 Mild (1 & 2)10957.3%
 Moderate (3)4322.7%
 Severe (4 & 5)3820.0%
Levodopa dosage (in LED mg)472.8510.1
Dopamine agonist usage (in LED mg)165.8219.3
Antiparkinson medication (in LED mg)677.5600.6
MDS-UPDRS nM-EDL13.17.5
MDS-UPDRS M-EDL13.99.1
MDS-UPDRS ME35.015.9
MDS-UPDRS MC4.43.4
Nonmotor Symptoms Scale53.938.8
Montreal Cognitive Assessment22.74.4
Beck Depression Inventory11.78.8
Lille Apathy Rating Scale−22.59.5
Hamilton Anxiety Scale13.16.7
Parkinson Anxiety Scale (Part A)7.04.6
Parkinson Anxiety Scale (Part B)2.42.9
Parkinson Anxiety Scale (Part C)1.92.3
Parkinson Anxiety Scale (total score)11.38.4

LED = levodopa equivalent dosage; MDS-UPDRS = Movement Disorders Society-sponsored version of Unified Parkinson’s Disease Rating Scale; MDS-UPDRS M-EDL = motor experiences of daily living (Part II of MDS-UPDRS); MDS-UPDRS nM-EDL = nonmotor experiences of daily living (Part I of MDS-UPDRS); SD = standard deviation.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.